<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64691</article-id><article-id pub-id-type="doi">10.7554/eLife.64691</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Disease related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-216204"><name><surname>Rathinaswamy</surname><given-names>Manoj K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-50216"><name><surname>Gaieb</surname><given-names>Zied</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216206"><name><surname>Fleming</surname><given-names>Kaelin D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216207"><name><surname>Borsari</surname><given-names>Chiara</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4688-8362</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216208"><name><surname>Harris</surname><given-names>Noah J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216209"><name><surname>Moeller</surname><given-names>Brandon J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216210"><name><surname>Wymann</surname><given-names>Matthias P</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3349-4281</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-14473"><name><surname>Amaro</surname><given-names>Rommie E</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-137057"><name><surname>Burke</surname><given-names>John E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7904-9859</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Biochemistry and Microbiology</institution>, <institution>University of Victoria</institution>, <addr-line><named-content content-type="city">Victoria</named-content></addr-line>, <country>Canada</country></aff><aff id="aff2"><institution content-type="dept">Department of Chemistry and Biochemistry</institution>, <institution>University of California, San Diego</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Biomedicine</institution>, <institution>University of Basel</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff4"><institution content-type="dept">Chemistry and Biochemistry, National Biomedical Computation Resource</institution>, <institution>University of California, San Diego</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-182970"><name><surname>Andreotti</surname><given-names>Amy</given-names></name><role>Reviewing editor</role><aff><institution>Iowa State University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>jeburke@uvic.ca</email> (JB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>04</day><month>03</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e64691</elocation-id><history><date date-type="received"><day>08</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>03</day><month>03</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Rathinaswamy et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Rathinaswamy et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64691-v1.pdf"/><abstract><p>Class I Phosphoinositide 3-kinases (PI3Ks) are master regulators of cellular functions, with the class IB PI3K catalytic subunit (p110g) playing key roles in immune signalling. p110g is a key factor in inflammatory diseases, and has been identified as a therapeutic target for cancers due to its immunomodulatory role. Using a combined biochemical/biophysical approach, we have revealed insight into regulation of kinase activity, specifically defining how immunodeficiency and oncogenic mutations of R1021 in the C-terminus can inactivate or activate enzyme activity. Screening of inhibitors using HDX-MS revealed that activation loop-binding inhibitors induce allosteric conformational changes that mimic those in the R1021C mutant. Structural analysis of advanced PI3K inhibitors in clinical development revealed novel binding pockets that can be exploited for further therapeutic development. Overall this work provides unique insights into regulatory mechanisms that control PI3Kg kinase activity, and shows a framework for the design of PI3K isoform and mutant selective inhibitors.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009326</institution-id><institution>Cancer Research Society</institution></institution-wrap></funding-source><award-id>CRS-24368</award-id><principal-award-recipient><name><surname>Burke</surname><given-names>John E</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000245</institution-id><institution>Michael Smith Foundation for Health Research</institution></institution-wrap></funding-source><award-id>17686</award-id><principal-award-recipient><name><surname>Burke</surname><given-names>John E</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source><award-id>New Investigator</award-id><principal-award-recipient><name><surname>Burke</surname><given-names>John E</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM132826</award-id><principal-award-recipient><name><surname>Gaieb</surname><given-names>Zied</given-names></name><name><surname>Amaro</surname><given-names>Rommie E</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008945</institution-id><institution>Stiftung FHNW</institution></institution-wrap></funding-source><award-id>341</award-id><principal-award-recipient><name><surname>Wymann</surname><given-names>Matthias P</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Swiss National Science</institution></institution-wrap></funding-source><award-id>310030_189065</award-id><principal-award-recipient><name><surname>Wymann</surname><given-names>Matthias P</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008273</institution-id><institution>Novartis Foundation</institution></institution-wrap></funding-source><award-id>14B095</award-id><principal-award-recipient><name><surname>Wymann</surname><given-names>Matthias P</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100013348</institution-id><institution>Innosuisse - Schweizerische Agentur für Innovationsförderung</institution></institution-wrap></funding-source><award-id>37213.1 IP-LS</award-id><principal-award-recipient><name><surname>Wymann</surname><given-names>Matthias P</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The crystallography data has been deposited in the protein data bank with accession numbers (PDB: 7JWE, 7JX0, 7JWZ). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository[83] with the dataset identifier PXD021132. All data generated or analyzed during this study are included in the manuscript and supporting files. Specifically biochemical kinase assay data are included in the source data files.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Tate JG</collab><collab>Bamford S</collab><collab>Jubb HC</collab><collab>Sondka Z</collab><collab>Beare DM</collab><collab>Bindal N</collab><collab>Boutselakis H</collab><collab>Cole CG</collab><collab>Creatore C</collab><collab>Dawson E</collab><collab>Fish P</collab><collab>Harsha B</collab><collab>Hathaway C</collab><collab>Jupe SC</collab><collab>Kok CY</collab><collab>Noble K</collab><collab>Ponting L</collab><collab>Ramshaw CC</collab><collab>Rye CE</collab><collab>Speedy HE</collab><collab>Stefancsik R</collab><collab>Thompson SL</collab><collab>Wang S</collab><collab>Ward S</collab><collab>Campbell PJ</collab><collab>Forbes SA</collab></person-group><year iso-8601-date="2019">2019</year><source>COSMIC: the Catalogue Of Somatic Mutations In Cancer</source><ext-link ext-link-type="uri" xlink:href="https://cancer.sanger.ac.uk/cosmic">https://cancer.sanger.ac.uk/cosmic</ext-link><comment>COSMIC</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Murray</collab><collab>J.M.</collab><collab>Ultsch</collab><collab>M.</collab></person-group><year iso-8601-date="2017">2017</year><source>PI3K-gamma K802T in complex with Cpd 8 10-((1-(tert-butyl)piperidin-4-yl)sulfinyl)-2-(1-isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6AUD">https://www.rcsb.org/structure/6AUD</ext-link><comment>PDB, 6AUD</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Knight</collab><collab>Z.A.</collab><collab>Gonzalez</collab><collab>B.</collab><collab>Feldman</collab><collab>M.E.</collab><collab>Zunder</collab><collab>E.R.</collab><collab>Goldenberg</collab><collab>D.D.</collab><collab>Williams</collab><collab>O.</collab><collab>Loewith</collab><collab>R.</collab><collab>Stokoe</collab><collab>D.</collab><collab>Balla</collab><collab>A.</collab><collab>Toth</collab><collab>B.</collab><collab>Balla</collab><collab>T.</collab><collab>Weiss</collab><collab>W.A.</collab><collab>Williams</collab><collab>R.L.</collab><collab>Shokat</collab><collab>K.M.</collab></person-group><year iso-8601-date="2006">2006</year><source>A pharmacological map of the PI3-K family defines a role for p110alpha in signaling: The structure of complex of phosphoinositide 3-kinase gamma with inhibitor PIK-90</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/2CHX">https://www.rcsb.org/structure/2CHX</ext-link><comment>PDB, 2CHX</comment></element-citation><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Camps</collab><collab>M.</collab><collab>Ruckle</collab><collab>T.</collab><collab>Ji</collab><collab>H.</collab><collab>Ardissone</collab><collab>V.</collab><collab>Rintelen</collab><collab>F.</collab><collab>Shaw</collab><collab>J.</collab><collab>Ferrandi</collab><collab>C.</collab><collab>Chabert</collab><collab>C.</collab><collab>Gillieron</collab><collab>C.</collab><collab>Francon</collab><collab>B.</collab><collab>Martin</collab><collab>T.</collab><collab>Gretener</collab><collab>D.</collab><collab>Perrin</collab><collab>D.</collab><collab>Leroy</collab><collab>D.</collab><collab>Vitte</collab><collab>P.-A.</collab><collab>Hirsch</collab><collab>E.</collab><collab>Wymann</collab><collab>M.P.</collab><collab>Cirillo</collab><collab>R.</collab><collab>Schwarz</collab><collab>M.K.</collab><collab>Rommel</collab><collab>C.</collab></person-group><year iso-8601-date="2005">2005</year><source>Crystal Structure of human PI3Kgamma complexed with AS604850</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/2a4z">https://www.rcsb.org/structure/2a4z</ext-link><comment>PDB, 2A4Z</comment></element-citation><element-citation id="dataset5" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Elkins</collab><collab>P.A.</collab><collab>Marrero</collab><collab>E.M.</collab></person-group><year iso-8601-date="2009">2009</year><source>Structure of Pi3K gamma with a potent inhibitor: GSK2126458</source><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/3L08">https://www.rcsb.org/structure/3L08</ext-link><comment>PDB, 3L08</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-64691-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>